Cephalon aims to switch patients from Provigil to Nuvigil

06/2/2009 | Wall Street Journal, The

Cephalon began selling Nuvigil tablets as part of a campaign to switch narcolepsy patients from Provigil, the biotech firm's blockbuster sleep-disorder drug nearing patent expiration. Cephalon's campaign also includes prescription savings that will lower a typical co-pay for Nuvigil to as little as $10.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ